APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pulmonary Embolism Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pulmonary Embolism Therapeutics Market Outlook and Growth Opportunities 2026

2 January 2026199 pages

Choose your research edition.

Industry ResearchPulmonary Embolism Therapeutics Industry Research Report 2026111 pages · $2,950 USDIndustry Growth & TrendsGlobal Pulmonary Embolism Therapeutics Industry Growth and Trends Forecast to 203287 pages · $3,450 USDMarket StructureGlobal Pulmonary Embolism Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032182 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pulmonary Embolism Therapeutics Market Outlook and Growth Opportunities 2026199 pages · $4,250 USDMarket Analysis & ForecastGlobal Pulmonary Embolism Therapeutics Market Analysis and Forecast 2026-2032197 pages · $4,950 USD

Market perspective

The global Pulmonary Embolism Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pulmonary Embolism Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pulmonary Embolism Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pulmonary Embolism Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pulmonary Embolism Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pulmonary Embolism Therapeutics market include Johnson & Johnson, F. Hoffmann-La Roche, Daiichi Sankyo, Bristol-Myers Squibb and Boehringer Ingelheim International, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Pulmonary Embolism Therapeutics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pulmonary Embolism Therapeutics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pulmonary Embolism Therapeutics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Pulmonary Embolism Therapeutics market.

Pulmonary Embolism Therapeutics Segment by Company

Johnson & Johnson

F. Hoffmann-La Roche

Daiichi Sankyo

Bristol-Myers Squibb

Boehringer Ingelheim International

Pulmonary Embolism Therapeutics Segment by Type

Oral

Parenteral

Pulmonary Embolism Therapeutics Segment by Application

Adult

Child

Pulmonary Embolism Therapeutics Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Colombia

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Pulmonary Embolism Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Pulmonary Embolism Therapeutics key companies, revenue, market share, and recent developments.

3. To split the Pulmonary Embolism Therapeutics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Pulmonary Embolism Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pulmonary Embolism Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Pulmonary Embolism Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Embolism Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Embolism Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Embolism Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pulmonary Embolism Therapeutics industry.

Chapter 3: Detailed analysis of Pulmonary Embolism Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Pulmonary Embolism Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Pulmonary Embolism Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pulmonary Embolism Therapeutics Industry Trends Table 2. Pulmonary Embolism Therapeutics Industry Drivers Table 3. Pulmonary Embolism Therapeutics Industry Opportunities and Challenges Table 4. Pulmonary Embolism Therapeutics Industry Restraints Table 5. Global Pulmonary Embolism Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pulmonary Embolism Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Pulmonary Embolism Therapeutics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Pulmonary Embolism Therapeutics Key Company Manufacturing Base & Headquarters Table 9. Global Pulmonary Embolism Therapeutics Company, Product Type & Application Table 10. Global Pulmonary Embolism Therapeutics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Pulmonary Embolism Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Oral Table 15. Significant Companies of Parenteral Table 16. Global Pulmonary Embolism Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Pulmonary Embolism Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Pulmonary Embolism Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Pulmonary Embolism Therapeutics Sales Value Share by Type (2021-2026) Table 20. Global Pulmonary Embolism Therapeutics Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Adult Table 22. Significant Companies of Child Table 23. Global Pulmonary Embolism Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 24. Global Pulmonary Embolism Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 25. Global Pulmonary Embolism Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 26. Global Pulmonary Embolism Therapeutics Sales Value Share by Application (2021-2026) Table 27. Global Pulmonary Embolism Therapeutics Sales Value Share by Application (2027-2032) Table 28. Global Pulmonary Embolism Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Pulmonary Embolism Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 30. Global Pulmonary Embolism Therapeutics Sales Value Share by Region (2021-2026) Table 31. Global Pulmonary Embolism Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 32. Global Pulmonary Embolism Therapeutics Sales Value Share by Region (2027-2032) Table 33. Global Pulmonary Embolism Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Pulmonary Embolism Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 35. Global Pulmonary Embolism Therapeutics Sales Value Market Share by Country (2021-2026) Table 36. Global Pulmonary Embolism Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 37. Global Pulmonary Embolism Therapeutics Sales Value Market Share by Country (2027-2032) Table 38. Johnson & Johnson Company Information Table 39. Johnson & Johnson Business Overview Table 40. Johnson & Johnson Pulmonary Embolism Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 41. Johnson & Johnson Pulmonary Embolism Therapeutics Product Portfolio Table 42. Johnson & Johnson Recent Development Table 43. F. Hoffmann-La Roche Company Information Table 44. F. Hoffmann-La Roche Business Overview Table 45. F. Hoffmann-La Roche Pulmonary Embolism Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. F. Hoffmann-La Roche Pulmonary Embolism Therapeutics Product Portfolio Table 47. F. Hoffmann-La Roche Recent Development Table 48. Daiichi Sankyo Company Information Table 49. Daiichi Sankyo Business Overview Table 50. Daiichi Sankyo Pulmonary Embolism Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Daiichi Sankyo Pulmonary Embolism Therapeutics Product Portfolio Table 52. Daiichi Sankyo Recent Development Table 53. Bristol-Myers Squibb Company Information Table 54. Bristol-Myers Squibb Business Overview Table 55. Bristol-Myers Squibb Pulmonary Embolism Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Bristol-Myers Squibb Pulmonary Embolism Therapeutics Product Portfolio Table 57. Bristol-Myers Squibb Recent Development Table 58. Boehringer Ingelheim International Company Information Table 59. Boehringer Ingelheim International Business Overview Table 60. Boehringer Ingelheim International Pulmonary Embolism Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. Boehringer Ingelheim International Pulmonary Embolism Therapeutics Product Portfolio Table 62. Boehringer Ingelheim International Recent Development Table 63. Research Programs/Design for This Report Table 64. Authors List of This Report Table 65. Secondary Sources Table 66. Primary Sources List of Figures Figure 1. Pulmonary Embolism Therapeutics Product Image Figure 2. Global Pulmonary Embolism Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pulmonary Embolism Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Pulmonary Embolism Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Oral Image Figure 8. Parenteral Image Figure 9. Global Pulmonary Embolism Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Pulmonary Embolism Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Pulmonary Embolism Therapeutics Sales Value Share by Type (2021-2032) Figure 12. Adult Image Figure 13. Child Image Figure 14. Global Pulmonary Embolism Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Pulmonary Embolism Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Pulmonary Embolism Therapeutics Sales Value Share by Application (2021-2032) Figure 17. Global Pulmonary Embolism Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 18. Global Pulmonary Embolism Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 19. North America Pulmonary Embolism Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 20. North America Pulmonary Embolism Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 21. Europe Pulmonary Embolism Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 22. Europe Pulmonary Embolism Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Asia-Pacific Pulmonary Embolism Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 24. Asia-Pacific Pulmonary Embolism Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 25. South America Pulmonary Embolism Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 26. South America Pulmonary Embolism Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 27. Middle East & Africa Pulmonary Embolism Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 28. Middle East & Africa Pulmonary Embolism Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 29. USA Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 30. USA Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 31. USA Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 32. Canada Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. Canada Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. Canada Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Mexico Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Mexico Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Mexico Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Germany Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Germany Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Germany Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. France Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. France Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. France Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. U.K. Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. U.K. Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. U.K. Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Italy Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Italy Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Italy Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Spain Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Spain Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Spain Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Russia Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Russia Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Russia Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Netherlands Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Netherlands Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Netherlands Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Nordic Countries Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Nordic Countries Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Nordic Countries Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. China Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. China Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. China Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Japan Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Japan Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Japan Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. South Korea Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. South Korea Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. South Korea Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. India Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. India Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. India Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. Australia Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. Australia Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. Australia Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Southeast Asia Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Southeast Asia Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Southeast Asia Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Brazil Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Brazil Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Brazil Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Argentina Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Argentina Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Argentina Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Chile Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Chile Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Chile Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Colombia Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Colombia Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Colombia Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Peru Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Peru Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Peru Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Saudi Arabia Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Saudi Arabia Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Israel Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Israel Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Israel Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. UAE Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. UAE Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. UAE Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Turkey Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Turkey Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Turkey Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Iran Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Iran Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Iran Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Egypt Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Egypt Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Egypt Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Years Considered Figure 114. Research Process Figure 115. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Parenteral
Applications
  • Adult
  • Child
Companies covered
  • Johnson & Johnson
  • F. Hoffmann-La Roche
  • Daiichi Sankyo
  • Bristol-Myers Squibb
  • Boehringer Ingelheim International

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Pulmonary Embolism Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Pulmonary Embolism Therapeutics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Pulmonary Embolism Therapeutics Market Dynamics
  1. 2.1 Pulmonary Embolism Therapeutics Industry Trends
  2. 2.2 Pulmonary Embolism Therapeutics Industry Drivers
  3. 2.3 Pulmonary Embolism Therapeutics Industry Opportunities and Challenges
  4. 2.4 Pulmonary Embolism Therapeutics Industry Restraints
3 Pulmonary Embolism Therapeutics Market by Company
  1. 3.1 Global Pulmonary Embolism Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Pulmonary Embolism Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Pulmonary Embolism Therapeutics Company Ranking (2024-2026)
  4. 3.4 Global Pulmonary Embolism Therapeutics Company Manufacturing Base and Headquarters
  5. 3.5 Global Pulmonary Embolism Therapeutics Company Product Type and Application
  6. 3.6 Global Pulmonary Embolism Therapeutics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Pulmonary Embolism Therapeutics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Pulmonary Embolism Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Pulmonary Embolism Therapeutics Market by Type
  1. 4.1 Pulmonary Embolism Therapeutics Type Introduction
  2. 4.1.1 Oral
  3. 4.1.2 Parenteral
  4. 4.2 Global Pulmonary Embolism Therapeutics Sales Value by Type
  5. 4.2.1 Global Pulmonary Embolism Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Pulmonary Embolism Therapeutics Sales Value by Type (2021-2032)
  7. 4.2.3 Global Pulmonary Embolism Therapeutics Sales Value Share by Type (2021-2032)
5 Pulmonary Embolism Therapeutics Market by Application
  1. 5.1 Pulmonary Embolism Therapeutics Application Introduction
  2. 5.1.1 Adult
  3. 5.1.2 Child
  4. 5.2 Global Pulmonary Embolism Therapeutics Sales Value by Application
  5. 5.2.1 Global Pulmonary Embolism Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Pulmonary Embolism Therapeutics Sales Value by Application (2021-2032)
  7. 5.2.3 Global Pulmonary Embolism Therapeutics Sales Value Share by Application (2021-2032)
6 Pulmonary Embolism Therapeutics Regional Value Analysis
  1. 6.1 Global Pulmonary Embolism Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pulmonary Embolism Therapeutics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Pulmonary Embolism Therapeutics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Pulmonary Embolism Therapeutics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Pulmonary Embolism Therapeutics Sales Value (2021-2032)
  7. 6.3.2 North America Pulmonary Embolism Therapeutics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Pulmonary Embolism Therapeutics Sales Value (2021-2032)
  10. 6.4.2 Europe Pulmonary Embolism Therapeutics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Pulmonary Embolism Therapeutics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Pulmonary Embolism Therapeutics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Pulmonary Embolism Therapeutics Sales Value (2021-2032)
  16. 6.6.2 South America Pulmonary Embolism Therapeutics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Pulmonary Embolism Therapeutics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Pulmonary Embolism Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Pulmonary Embolism Therapeutics Country-level Value Analysis
  1. 7.1 Global Pulmonary Embolism Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pulmonary Embolism Therapeutics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Pulmonary Embolism Therapeutics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Pulmonary Embolism Therapeutics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Pulmonary Embolism Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Pulmonary Embolism Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Pulmonary Embolism Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Johnson & Johnson
  2. 8.1.1 Johnson & Johnson Company Information
  3. 8.1.2 Johnson & Johnson Business Overview
  4. 8.1.3 Johnson & Johnson Pulmonary Embolism Therapeutics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Johnson & Johnson Pulmonary Embolism Therapeutics Product Portfolio
  6. 8.1.5 Johnson & Johnson Recent Developments
  7. 8.2 F. Hoffmann-La Roche
  8. 8.2.1 F. Hoffmann-La Roche Company Information
  9. 8.2.2 F. Hoffmann-La Roche Business Overview
  10. 8.2.3 F. Hoffmann-La Roche Pulmonary Embolism Therapeutics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 F. Hoffmann-La Roche Pulmonary Embolism Therapeutics Product Portfolio
  12. 8.2.5 F. Hoffmann-La Roche Recent Developments
  13. 8.3 Daiichi Sankyo
  14. 8.3.1 Daiichi Sankyo Company Information
  15. 8.3.2 Daiichi Sankyo Business Overview
  16. 8.3.3 Daiichi Sankyo Pulmonary Embolism Therapeutics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Daiichi Sankyo Pulmonary Embolism Therapeutics Product Portfolio
  18. 8.3.5 Daiichi Sankyo Recent Developments
  19. 8.4 Bristol-Myers Squibb
  20. 8.4.1 Bristol-Myers Squibb Company Information
  21. 8.4.2 Bristol-Myers Squibb Business Overview
  22. 8.4.3 Bristol-Myers Squibb Pulmonary Embolism Therapeutics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Bristol-Myers Squibb Pulmonary Embolism Therapeutics Product Portfolio
  24. 8.4.5 Bristol-Myers Squibb Recent Developments
  25. 8.5 Boehringer Ingelheim International
  26. 8.5.1 Boehringer Ingelheim International Company Information
  27. 8.5.2 Boehringer Ingelheim International Business Overview
  28. 8.5.3 Boehringer Ingelheim International Pulmonary Embolism Therapeutics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Boehringer Ingelheim International Pulmonary Embolism Therapeutics Product Portfolio
  30. 8.5.5 Boehringer Ingelheim International Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst